Verici DX Logo

News

Clinical Validation Study Update

April 1, 2022
Strategic decision to expand study without impacting commercial pathway
Keep Reading

TR-1: Standard form for notification of major holdings

March 23, 2022
Notification of major holdings
Keep Reading

TR-1: Standard form for notification of major holdings

March 21, 2022
Notification of major holdings
Keep Reading

TR-1: Standard form for notification of major holdings

March 18, 2022
Notification of major holdings
Keep Reading

TR-1: Standard form for notification of major holdings

March 16, 2022
Notification of major holdings
Keep Reading

TR-1: Standard form for notification of major holdings

March 15, 2022
Notification of major holdings
Keep Reading

Close of Subscription and Fundraise Update

March 11, 2022
The Subscription has now closed and the Fundraise has successfully concluded, save for Admission.
Keep Reading

Fundraise - Successful Placing

March 4, 2022
Verici Dx is pleased to announce the successful completion of the Placing.
Keep Reading

Close of Accelerated Bookbuild

March 4, 2022
Further to the announcement made at 7.10 a.m. today, the Placing has now closed and the Bookbuild has been successfully concluded.
Keep Reading

Proposed Fundraise to raise not less than £10.0 million (approximately $13.3 million)

March 4, 2022
Verici Dx announces its intention to conduct a fundraise through the non pre-emptive issue of at least 28,571,429 new ordinary shares
Keep Reading

Archived News

crossmenuchevron-down